Evidence map›Paper›PMID 39020142›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024

Acute, chronic and conditioned effects of intranasal oxytocin in the mu-opioid receptor knockout mouse model of autism: Social context matters.

Fani Pantouli, Camille N Pujol, Cécile Derieux, Mathieu Fonteneau, Lucie P Pellissier, Claire Marsol, Julie Karpenko, Dominique Bonnet, Marcel Hibert, Alexis Bailey and 2 more

Abstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fani Pantouli *INRAE, CNRS, Université de Tours, Inserm, PRC, 37380, Nouzilly, France.
Camille N Pujol *INRAE, CNRS, Université de Tours, Inserm, PRC, 37380, Nouzilly, France.
Cécile DerieuxINRAE, CNRS, Université de Tours, Inserm, PRC, 37380, Nouzilly, France.
Mathieu FonteneauUMR1253, iBrain, Université de Tours, Inserm, CNRS, Faculté des Sciences et Techniques, Parc de Grandmont, 37200, Tours, France.ORCID http://orcid.org/0000-0002-0028-4133
Lucie P PellissierINRAE, CNRS, Université de Tours, Inserm, PRC, 37380, Nouzilly, France.
Claire MarsolLaboratoire d'Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 route du Rhin, 67412, Illkirch, France.
Julie KarpenkoLaboratoire d'Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 route du Rhin, 67412, Illkirch, France.
Dominique BonnetLaboratoire d'Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 route du Rhin, 67412, Illkirch, France.
Marcel HibertLaboratoire d'Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 route du Rhin, 67412, Illkirch, France.
Alexis BaileyPharmacology section, Institute of Medical and Biomedical Education, St George's University of London, London, SW17 ORE, UK.
Julie Le Merrer *INRAE, CNRS, Université de Tours, Inserm, PRC, 37380, Nouzilly, France. Julie.le-merrer@inserm.fr.ORCID http://orcid.org/0000-0002-8670-4273
Jerome A J Becker *INRAE, CNRS, Université de Tours, Inserm, PRC, 37380, Nouzilly, France. Jerome.becker@inserm.fr.ORCID http://orcid.org/0000-0002-0039-0067

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autism Spectrum Disorders (ASD) are neurodevelopmental disorders whose diagnosis relies on deficient social interaction and communication together with repetitive behaviours. Multiple studies have highlighted the potential of oxytocin (OT) to ameliorate behavioural abnormalities in animal models and subjects with ASD. Clinical trials, however, yielded disappointing results. Our study aimed at assessing the behavioural effects of different regimens of OT administration in the Oprm1 null mouse model of ASD. We assessed the effects of intranasal OT injected once at different doses (0.15, 0.3, and 0.6 IU) and time points (5, 15, and 30 min) following administration, or chronically, on ASD-related behaviours (social interaction and preference, stereotypies, anxiety, nociception) in Oprm1

Indexed as

Administration, IntranasalDisease Models, AnimalMice, KnockoutOxytocinReceptors, Opioid, muSocial BehaviorAnimalsAutism Spectrum DisorderFemaleMaleMiceMice, Inbred C57BLOprm protein, mouseOxytocinReceptors, Opioid, mu

Identifiers

PMID39020142
PMCPMC11473707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.